photo
Speaker

Keith Ward

PRESIDENT & CHIEF EXECUTIVE OFFICER, INTERVEXION THERAPEUTICS
Little Rock, Arkansas, United States
Keith W. Ward, PhD, the Company’s Chief Executive Officer, joined InterveXion in 2019, and brings significant C-level biotech leadership experience to the company. Prior to joining InterveXion, Dr. Ward served as Executive Vice President and Chief Development Officer for Reata Pharmaceuticals, where he led research and development, clinical operations, regulatory affairs, manufacturing, and project management. Before that, Dr. Ward developed ophthalmic pharmaceuticals and medical devices as Global Vice President of Pharmaceutical R&D for Bausch & Lomb. Dr. Ward has also held positions of increasing responsibility within GlaxoSmithKline and SmithKline Beecham Pharmaceuticals. Dr. Ward earned a B.S. in Toxicology with a minor in Chemistry from Northeast Louisiana University and a Ph.D. in Toxicology from The University of North Carolina at Chapel Hill.
Speaking In
[Available On-Demand]
InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical company developing…